Loading...
•
Mar 31, 2021
Fate Therapeutics Q1 2021 Earnings Report
Fate Therapeutics' financial position was strengthened and its off-the-shelf, iPSC-derived NK cell pipeline was successfully positioned to achieve significant clinical milestones.
Key Takeaways
Fate Therapeutics reported its Q1 2021 financial results, including revenue of $11.1 million. The company's cash, cash equivalents, and investments totaled $888.4 million and the company raised $460 million through a public offering.
IND Application Allowed by FDA for FT538 in Solid Tumors; Clinical Trial to Commence in 2021
Phase 1 Data from FT516 and FT538 Programs in Relapsed / Refractory Acute Myeloid Leukemia to be Featured at Investor Event on May 13
New Data from FT516 Phase 1 Study in Relapsed / Refractory Lymphoma to be Presented at 2021 American Society of Clinical Oncology Annual Meeting
Completed $460 Million Public Offering.
Fate Therapeutics
Fate Therapeutics
Fate Therapeutics Revenue by Segment
Revenue by Segment
Collaboration Revenue
CapyFin.com